JP Morgan Chase
XERS icon

JP Morgan Chase’s Xeris Biopharma Holdings XERS Stock Holding History

JP Morgan Chase’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-173,700
Closed -$1.01M – 5971
2020
Q3 		$1.01M Buy
+173,700
New +$695K ﹤0.01% 3640

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase's XERS Position: Q2 2026 in Review

JP Morgan Chase increased its Xeris Biopharma Holdings (XERS) stake by 73% in Q2 2026, buying an estimated $2.85M and bringing the position to 1,058,067 shares worth $8.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2990.

JP Morgan Chase first reported a position in XERS in Q3 2018 and has held it in 32 quarters since. The position peaked at $11.6M in Q1 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • JP Morgan Chase held 1,058,067 shares of Xeris Biopharma Holdings worth $8.19M as of Q2 2026.
  • JP Morgan Chase bought 445,588 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.85M.
  • Xeris Biopharma Holdings made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2990 holding.
  • JP Morgan Chase first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 32 quarters since.
  • JP Morgan Chase's Xeris Biopharma Holdings position peaked at $11.6M in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.